Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Sysmex instrumentation helps optimise clinical trial performance

Sysmex America : 24 May, 2007  (New Product)
Sysmex America's instrument technology has been actively involved with Genzyme in the company's multinational Phase II clinical drug trial programme.
Application of the newly available IPF parameter (Immature Platelet Fraction), a reticulated platelet equivalent, is an additional reason for the inclusion of Sysmex XE 2100 instruments into the clinical trial arena.

The IPF parameter is a direct extension of the fluorescent optical platelet count, available on Sysmex automated cell counters, due to the use of proprietary Polymethine fluorescent dyes with nucleic acid affinity.

This fluorescence flow cytometry is applied to all cells analysed on the XE2100 instrument, and is responsible for the enhanced analytical sensitivity that is being appreciated by both routine laboratories, and clinical research institutions.

The ability to accurately quantify immature cells (Immature Granulocytes, Reticulocytes, and Immature Platelets) is a feature of Sysmex reagent technology that is becoming increasingly attractive from the clinical research perspective, since immature cells more acutely reflect changes that occur in response to drug administration or changes in disease progression.

Clinical applications of the IPF parameter include differentiation between thrombocytopenia due to bone marrow suppression, and thrombocytopenia due to peripheral platelet destruction.

Contracts were recently signed which enable a research collaboration between Sysmex and Genzyme using samples from Genzyme's multinational Phase II clinical drug trial.

The trial involves investigating the treatment efficacy of the drug alemtuzumab in patients with early, active relapsing-remitting Multiple Sclerosis.

This is the first of many potential clinical trial applications of the IPF parameter.
ITP treatment options include: IVIG, Anti-D and steroids, to prevent peripheral destruction of platelets; and newer therapies that induce thrombopoiesis.

A presentation on the use of the Sysmex XE 2100 instrument Immature Platelet Fraction was recently presented at the International Society of Laboratory Hematology (ISLH) meeting in Miami, Florida, USA, by Genzyme's Dr Mark Goldberg, senior vice president clinical research.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo